G
Galectin Therapeutics Inc. (GALT)
NCM – Real Time Price. Currency in USD
2.25
+0.04 (1.81%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.25
+0.04 (1.81%)
At close: May 12, 2026, 4:00 PM EDT
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company’s lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
| Name | Position |
|---|---|
| Dr. Khurram Jamil M.D. | Chief Medical Officer |
| Mr. Jack W. Callicutt CPA | CFO, Treasurer & Corporate Secretary |
| Mr. Jim Wilkins Ph.D. | Head of CMC & Pharmaceutical Development |
| Mr. Joel Lewis CPA | President & CEO |
| Mr. Robert Tritt J.D. | General Counsel |
| Ms. Beth Knowles | Executive Assistant & Officer Manager |
| Date | Type | Document |
|---|---|---|
| 2026-04-08 | CORRESP | filename1.htm |
| 2026-03-31 | 8-K | ef20068722_8k.htm |
| 2026-03-31 | 10-K | ef20060823_10k.htm |
| 2026-03-17 | 8-K | ef20068034_8k.htm |
| 2026-01-21 | 8-K | ef20063365_8k.htm |
| 2026-01-12 | 8-K | ef20062754_8k.htm |
| 2025-12-19 | 8-K | ef20061484_8k.htm |
| 2025-12-08 | 8-K | ef20060738_8k.htm |
| 2025-12-03 | 8-K | ef20060348_8k.htm |
| 2025-11-14 | 8-K | ny20058903x1_8k.htm |